{
  "source": "PA-Notification-Demser.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1450-1\nProgram Prior Authorization/Notification\nMedications Demser® (metyrosine)\nP&T Approval Date 7/2024\nEffective Date 1/1/2025\n1. Background:\nDemser is indicated in the treatment of patients with pheochromocytoma for preoperative\npreparation of patients for surgery, management of patients when surgery is contraindicated, and\nthe chronic treatment of patients with malignant pheochromocytoma. Demser is not\nrecommended for the control of essential hypertension.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Demser will be approved based on the following criterion:\na. Diagnosis of pheochromocytoma\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Demser will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Demser [package insert]. Bridgewater, NJ: Bausch Health, LLC; July 2021.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Demser\nChange Control\n7/2024 New program.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}